BiotechTube

Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2C

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkins Lymphoma

Conditions

Non-Hodgkins Lymphoma

Trial Timeline

May 8, 2018 → Oct 16, 2026

NCT ID
NCT03533283

About Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2C

Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2C is a phase 1/2 stage product being developed by Roche for Non-Hodgkins Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03533283. Target conditions include Non-Hodgkins Lymphoma.

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03533283Phase 1/2Active

Competing Products

15 competing products in Non-Hodgkins Lymphoma

See all competitors
ProductCompanyStageHype Score
Acalabrutinib + ACP-319AstraZenecaPhase 1/2
32
JBH492NovartisPhase 1
21
Obinutuzumab + Glofitamab + Gemcitabine + OxaliplatinRochePhase 2
42
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + RituximabAmgenPhase 2
35
hLL2 (epratuzumab)Gilead SciencesPhase 1
21
Velcade + TemsirolimusPfizerPhase 2
35
alemtuzumabSanofiPhase 1/2
24
Odronextamab + REGN5837Regeneron PharmaceuticalsPhase 1
36
Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + FludarabineBayerPhase 1/2
25
Rituximab + Fludarabine + CAMPTH-1HBayerPhase 2
32
Rituximab + CHOP + CVP + Ibritumomab TiuxetanBiogenPhase 2
32
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y ZevalinBiogenPhase 2
32
UblituximabTG TherapeuticsPhase 1/2
29
Ublituximab + LenalidomideTG TherapeuticsPhase 1
18
XmAb13676XencorPhase 1
23